SEC Company Response from Addex Therapeutics (ADXN) — Aug 25, 2022
Addex Therapeutics Ltd.
Date: Aug. 25, 2022 · CIK: 0001574232 · Accession: 0001104659-22-094419
AI Filing Summary & Sentiment
File numbers found in text: 333-266995
Letter
Addex Therapeutics Ltd
Chemin des Mines 9,
CH-1202 Geneva, Switzerland
August 25, 2022 Via Edgar
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Michael Davis
Celeste Murphy
RE: Addex Therapeutics Ltd
Registration Statement on Form F-1
File No. 333-266995
Acceleration Request
Requested Date: August 29, 2022
Requested Time: 4:00 P.M. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form F-1 (File No. 333-266995) (the “Registration Statement”) to become effective on August 29, 2022, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Josh Kaufman, counsel to the Registrant, at (212) 479-6495.
Very truly yours,
Addex Therapeutics Ltd.
Show Raw Text
CORRESP
1
filename1.htm
Addex Therapeutics
Ltd
Chemin des Mines 9,
CH-1202 Geneva, Switzerland
August 25, 2022 Via Edgar
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn:
Michael Davis
Celeste Murphy
RE: Addex Therapeutics Ltd
Registration Statement on Form F-1
File No. 333-266995
Acceleration Request
Requested Date:
August 29, 2022
Requested Time:
4:00 P.M. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities
Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and
Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form F-1 (File No. 333-266995) (the
“Registration Statement”) to become effective on August 29, 2022, at 4:00 p.m., Eastern Time, or as soon thereafter
as is practicable.
Once the Registration Statement has been declared
effective, please orally confirm that event with Josh Kaufman, counsel to the Registrant, at (212) 479-6495.
Very truly yours,
Addex Therapeutics Ltd.
/s/ Tim Dyer
Tim Dyer
Chief Executive Officer
cc:
Josh Kaufman, Cooley LLP
Marc Recht, Cooley LLP
David C. Boles, Cooley (UK) LLP
Frank Gerhard, Homburger AG